Why Asthma Research Matters Now More Than Ever
The landscape of asthma treatment is shifting. The old model—step up inhaled steroids, add a long-acting bronchodilator, maybe try a leukotriene receptor antagonist—worked for a generation but left too many people behind. What has changed is the recognition that asthma is not one disease. It is a collection of different inflammatory patterns, and they respond to different interventions.
In the UK, researchers have been at the centre of this shift. The Manchester Asthma and Allergy Study, a birth cohort that has followed participants for over two decades, has helped identify which children are likely to outgrow their wheeze and which will carry asthma into adulthood. The Wessex AsThma CoHort in Southampton has been mapping the real-world trajectory of difficult asthma, revealing just how varied the patient experience can be. And the introduction of biologic therapies—treatments that target specific inflammatory pathways rather than blanketing the immune system—has fundamentally altered what is possible for people with severe eosinophilic or allergic asthma.
Seven biologic treatments are now available on the NHS for severe asthma. That is a remarkable number, and it reflects the pace of discovery. But it also creates a challenge: with so many options, how do clinicians match the right treatment to the right patient? That question is being answered through ongoing trials. The recent UK approval of depemokimab, a biologic that requires only two injections per year, signals just how far the field has come. For patients who previously had to visit a hospital clinic every few weeks, this kind of innovation changes daily life.
Beyond biologics, researchers are exploring entirely different angles. A study at the University of Salford is investigating whether techniques borrowed from neurological physiotherapy—normally used for conditions like joint pain—could help people with asthma gain better control over their breathing muscles. Another project at Imperial College London is building a respiratory data hub that maps asthma prevalence across diverse populations in north-west London, aiming to understand why certain communities carry a heavier burden of disease.
What Participation Actually Looks Like
If you have never been involved in a clinical trial, the process can seem opaque. Here is what typically happens.
After expressing interest—either through your GP, a hospital consultant, or by finding a study online—you will have an initial conversation with the research team. They will explain the purpose of the trial, what the treatment involves, how often you would need to visit the clinic, and what the potential risks and benefits are. This is not a sales pitch. The team is ethically required to make sure you understand what you are signing up for, and you can withdraw at any time.
If you decide to proceed, there is usually a screening visit. This might involve blood tests, lung function measurements (spirometry, sometimes more advanced tests like fractional exhaled nitric oxide), and a review of your medical history. Not everyone who is screened will qualify. Trials have strict inclusion and exclusion criteria—for example, a study testing a new biologic for eosinophilic asthma will need participants whose blood eosinophil counts fall within a specific range.
Once enrolled, the level of commitment varies. Some trials require monthly hospital visits for an injection or infusion. Others might only need you to attend every few months. There are also observational studies where you simply continue your normal treatment while researchers collect data on your symptoms and quality of life. The Manchester Asthma and Allergy Study, for instance, is purely observational—participants attend periodic assessments, and the data feeds into long-term understanding of how asthma evolves.
A common concern is cost. In the UK, clinical trial participation does not involve direct payment to the research team. The investigational treatment and all trial-related procedures are covered by the study sponsor, which is typically a pharmaceutical company, a university, or the National Institute for Health and Care Research. Some trials also reimburse reasonable travel expenses and may offer compensation for time, though this varies by study and location.
The table below outlines the main types of asthma trials currently recruiting in the UK and what they tend to involve.
| Trial Type | Example | Typical Duration | Suitable For | What It Offers | What to Consider |
|---|
| Biologic therapy trial | Depemokimab studies; benralizumab comparisons | 12-52 weeks | Severe eosinophilic or allergic asthma, uncontrolled on high-dose ICS | Access to cutting-edge targeted therapies; reduced exacerbation risk | Frequent monitoring visits; possible placebo arm |
| Inhaled therapy trial | New ICS/LAMA/LABA combinations | 8-24 weeks | Moderate to severe asthma | Novel delivery devices; potential improved symptom control | May require washout of current medications |
| Non-pharmacological intervention | Breathing retraining studies (e.g. Salford physiotherapy trial) | 6-12 weeks | Adults with persistent breathlessness despite medication | Drug-free approach; transferable self-management skills | Time commitment for weekly sessions; smaller studies |
| Observational cohort | WATCH study; MAAS follow-up | 1-10+ years | Any asthma severity | Contributes to long-term research; no treatment changes required | No direct therapeutic benefit; requires long-term commitment |
| Questionnaire/survey study | Royal Devon biologics experience survey | Single session | Patients on or starting biologic therapy | Minimal time commitment; can be done remotely | No clinical intervention; purely data collection |
Finding a Trial That Fits
The UK has several platforms that list actively recruiting asthma studies. The ISRCTN registry is a primary source, cataloguing trials from across the country with detailed eligibility criteria. The NIHR website also hosts a searchable database, and sites like clinicaltrialsuk.org.uk aggregate studies in plain English. Your respiratory consultant or specialist asthma nurse is often the best starting point, as they will know which trials are recruiting at your local hospital trust.
Geography matters. Major research hubs cluster around university hospitals: the Royal Brompton in London, the Manchester University NHS Foundation Trust, University Hospital Southampton, and the Glenfield Hospital in Leicester all run multiple respiratory trials. If you live in a rural area, you may need to travel, and that is worth factoring into your decision. Some trials now incorporate remote monitoring—using apps and home spirometry devices—to reduce the number of in-person visits, though this is more common in later-phase studies.
It is also worth noting that the NHS has been actively trying to broaden participation in research. Historically, clinical trials have struggled to recruit participants from ethnic minority backgrounds and from areas with higher levels of deprivation—the very populations that often carry a disproportionate asthma burden. Recent initiatives from the NIHR have focused on making trial information more accessible and on working with community organisations to build trust. If you belong to a group that has been underrepresented in research, your participation carries particular value.
Practical Steps to Get Started
Speak with your GP or asthma nurse first. They can tell you whether your asthma severity and phenotype align with the kinds of trials currently recruiting. Not every person with asthma is a candidate for a trial, and that is normal—trial criteria are deliberately narrow to produce clear results.
Search the ISRCTN registry or the NIHR website using terms like "asthma" plus your location. Read the participant information sheets carefully. These documents, while long, spell out exactly what is expected of you and what you can expect in return.
Ask questions before committing. How many visits are involved? Will you need to stop any current medications? Is there a possibility of receiving a placebo, and if so, for how long? What happens when the trial ends—will you be able to continue accessing the treatment if it works for you? A reputable research team will welcome these questions and answer them clearly.
Consider the emotional side too. Being in a trial can feel hopeful—you are contributing to science and may gain access to a treatment that changes your life. But it can also feel uncertain, particularly if you are randomised to a placebo arm or if the treatment does not work as hoped. Having a support system, whether that is family, friends, or a patient group like Asthma + Lung UK, can make a difference.
The research community in Britain has built something genuinely valuable: a network of investigators, clinicians, and patients working together to move asthma care forward. Whether you are newly diagnosed and curious about what the future holds, or you have been living with severe asthma for years and feel you have exhausted your options, the trials landscape is worth exploring. It might not be the right path for everyone, but for those it fits, it can open doors that were not there before.
研究の知恵